No significant differences were found for hypovolemia, renal impairment or failure, fracture, diabetic ketoacidosis (DKA), amputation, and severe hypoglycemia between the SGLT-2 inhibitor and the placebo groups.<h4>Conclusion</h4>In patients with T2DM, dapagliflozin was associated with an increased risk of RTIs, pollakiuria, and UTIs. The gene discussed is SLC5A2; the disease is type 2 diabetes mellitus.